Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

288

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab rezetecan
DRUG: Pyrotinib
DRUG: Dalpiciclib
DRUG: Trastuzumab
DRUG: ET: Letrozole/ Anastrozole/ Exemestane/ Fulvestrant/ Leuprorelin/ Goserelin.

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]